Stilbenoids from Gnetum macrostachyum Attenuate Human Platelet Aggregation and Adhesion

Abstract

Platelets play a critical role in pathogenesis of cardiovascular disorders and strokes. The inhibition of platelet function is beneficial for the treatment and prevention of these diseases. The phytochemical investigation of stilbenoids from Gnetum macrostachyum Hook. f. led to the isolation of trans-resveratrol (1), isorhapotigenin (2), gnetol (3), bisisorhapontigenin B (4), gnetin C (5), parvifolol A (6), latifolol (7) and gnetuhainin C (8). The isolated stilbenoids were evaluated for in vitro antiplatelet activities via agonist-induced platelet aggregation and static platelet-collagen adhesion assays using washed human platelets. Compounds 1, 2 and 3 were active in the inhibition of arachidonic acid (AA)-induced platelet aggregation. Compound 2 and its dimer, compound 4, were the most active stilbenoids in thrombin-induced platelet aggregation. Moreover, compounds 4, 5 and 6, tended to be more potent than monomeric and trimeric stilbenoids in a human platelet-collagen adhesion assay under static conditions. This is the first report of the antiplatelet activity of stilbenoids isolated from G. macrostachyum.

Anti‐platelet Activity of Erythro‐(7S,8R)‐7‐acetoxy‐3,4,3′,5′‐tetramethoxy‐8‐O‐4′‐neolignan from Myristica fragrans

“…the cost for lifetime management of cardiovascular risks (Barrett et al ., ). In this regard, much attention has been given to the development of herbal medicines for preventive treatment against cardiovascular diseases for their merits in safety and nature‐friendly image (Hu ; Kang et al ., ; Park et al ., ; Kloypan et al ., ). The present study has shown that EATN, a neolignan from M. fragrans , inhibited platelet aggregation induced by thrombin and PAF, without affecting platelet damage.…”

“…However, chemically synthesized or biologically modified drugs are frequently associated with serious adverse effects, such as internal bleeding and gastrointestinal adverse effects, casting doubt on their health benefit vs. the cost for lifetime management of cardiovascular risks (Barrett et al, 2008). In this regard, much attention has been given to the development of herbal medicines for preventive treatment against cardiovascular diseases for their merits in safety and nature-friendly image (Hu 2003;Kang et al, 2003;Park et al, 2008;Kloypan et al, 2012). The present study has shown that EATN, a neolignan from M. fragrans, inhibited platelet aggregation induced by thrombin and PAF, without affecting platelet damage.…”

“…; Kloypan et al . ). A variety of natural products that possess anti‐platelet activity have been reported in the literature, the majority of which are flavonoids, alkaloids, stilbenoids and phenolic compounds (Xiang et al .…”

“…Anti-platelet treatment has been established as a cornerstone in the management of atherothrombotic diseases. Although several types of anti-platelet drugs are clinically utilized for the therapeutic purposes of thrombosis, natural product-derived anti-platelet agents have also been extensively investigated (Kang et al 2003;Park et al 2008;Kloypan et al 2012). A variety of natural products that possess anti-platelet activity have been reported in the literature, the majority of which are flavonoids, alkaloids, stilbenoids and phenolic compounds (Xiang et al 2008).…”

Preclinical Pharmacokinetics and Pharmacodynamics and Content Analysis of Gnetol in Foodstuffs

“…However, only a few publications have documented activities of gnetol including strong inhibitory action on tyrosinase, the rate‐limiting enzyme in melanin synthesis, and the ability to inhibit melanogenesis in murine B16 melanoma cells (Ohguchi et al , ). Gnetol has also demonstrated antiplatelet activity (Kloypan et al , ). Additionally, gnetol has shown potential anti‐Alzheimer's disease activity via inhibition of acetylcholinesterase and butyrylcholinesterase (greater activity than resveratrol) (Sermboonpaisam and Sawasdee, ).…”